ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.

The ARK Genomic Revolution ETF (ARKG) and the Global X Genomics & Biotechnology ETF (GNOM) both focus on genomics but differ in strategy and risk. ARKG is an active fund concentrated on early-stage, unprofitable biotech innovators, showing higher volatility and a 32% gain year-to-date in 2026. GNOM is a passive fund tracking a broader index with established biotech firms like Moderna, offering more stability and a 17% gain in 2026. Over five years, ARKG fell 55.4% while GNOM dropped 42.6%, reflecting the risk premium for small-cap biotech. For retirement investors, GNOM is safer as a core holding, while ARKG suits those seeking higher risk and potential reward in gene-editing breakthroughs, especially if biotech M&A and falling rates resume.